<DOC>
	<DOC>NCT01820858</DOC>
	<brief_summary>This randomized trial is studying the efficacy and safety of the chemotherapy compared with radiation therapy alone as adjuvant treatment after operation in Patients with high risk and Stage I endometrial carcinoma.</brief_summary>
	<brief_title>The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>FIGO stage: Ⅰ, endometrial carcinoma; Female, Chinese women; Initial treatment is staging surgery; Pathological diagnosis: Endometrial adenocarcinoma; Pathologic examination and meet the following one of the indications of adjuvant therapy: ① histopathological grading in poorly differentiated: G3; ② ≥50% myometrial invasion; ③ vascular space involvement; No prior treatment; Provide written informed consent. Unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy; Family history of ovarian cancer; Suffering from other malignancies; Concurrently participating in other clinical trials; Unable or unwilling to sign informed consents; Unable or unwilling to abide by protocol.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>